Compare AMWL & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | STTK |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.4M | 119.0M |
| IPO Year | 2020 | 2020 |
| Metric | AMWL | STTK |
|---|---|---|
| Price | $3.96 | $3.01 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $8.33 | $4.00 |
| AVG Volume (30 Days) | 109.3K | ★ 235.9K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $265,023,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.71 | $0.69 |
| 52 Week High | $12.95 | $3.38 |
| Indicator | AMWL | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 36.58 | 73.92 |
| Support Level | $3.98 | $1.93 |
| Resistance Level | $4.22 | $2.18 |
| Average True Range (ATR) | 0.20 | 0.22 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 51.85 | 73.67 |
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.